Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

122.73USD
24 Feb 2017
Change (% chg)

$1.03 (+0.85%)
Prev Close
$121.70
Open
$121.85
Day's High
$122.74
Day's Low
$121.42
Volume
3,280,595
Avg. Vol
2,387,380
52-wk High
$126.07
52-wk Low
$102.98

Latest Key Developments (Source: Significant Developments)

Actelion says in discussions with another party regarding possible strategic transaction
Tuesday, 13 Dec 2016 08:11pm EST 

Actelion Ltd : Actelion - Actelion is engaged in discussions with another party regarding a possible strategic transaction . Actelion update on strategic transaction discussions . Actelion - Confirms that J&J has withdrawn from the discussions .Actelion - There can be no certainty at this point that any transaction will result.  Full Article

Actelion has given J&J access to some of its financial information as part of the deal negotiations - Bloomberg, citing sources
Tuesday, 29 Nov 2016 11:05am EST 

: Actelion has given J&J access to some of its financial information as part of the deal negotiations - Bloomberg, citing sources .One option being discussed is creating separate entity for Actelion's experimental drugs & research activities - Bloomberg, citing sources.  Full Article

J&J said to make takeover approach for Swiss drugmaker Actelion - Bloomberg
Thursday, 24 Nov 2016 01:55pm EST 

:J&J said to make takeover approach for Swiss drugmaker Actelion - Bloomberg, citing sources.  Full Article

Genmab announces U.S. FDA approval of Darzalex (Daratumumab) for relapsed multiple myeloma
Monday, 21 Nov 2016 03:46pm EST 

Genmab A/S : Genmab announces U.S. FDA approval of Darzalex (Daratumumab) for relapsed multiple myeloma and updates financial guidance . Genmab will receive milestone payments totaling $65 million from Janssen . Genmab says anticipate that 2016 operating expenses will remain in range of DKK 800 - 850 million . We expect 2016 revenue to be in range of DKK 1,650 million - 1,700 million, an increase of DKK 450 million compared to previous guidance . Genmab says now expect operating income for 2016 to be approximately DKK 825 - 875 million .Expect FY 2016 Darzalex royalties to remain in range of DKK 400 million - 450 million.  Full Article

Janssen's Guselkumab shows promise in psoriatic arthritis treatment in Phase 2 trial
Tuesday, 15 Nov 2016 08:00am EST 

Johnson & Johnson : Janssen - two serious AES were reported in study including one knee injury and one myocardial infarction . Janssen- safety observations through week 24 showed that 36 percent versus 32.7 percent experienced adverse events, in Guselkumab and placebo groups, respectively . Janssen - Guselkumab phase 2 results in active psoriatic arthritis follow positive phase 3 study results in moderate to severe plaque psoriasis . Janssen - there were no serious infections, malignancies, or deaths through week 24 . Janssen - plan to advance Guselkumab into a phase 3 psoriatic arthritis development program next year .Janssen next-generation biologic Guselkumab shows promise in the treatment of psoriatic arthritis in phase 2 trial.  Full Article

Paulson & Co cuts share stake in Alexion Pharmaceuticals, Johnson & Johnson
Monday, 14 Nov 2016 05:38pm EST 

Paulson & Co : Paulson & Co cuts share stake in Alexion Pharmaceuticals Inc by 15.0 percent to 227,700 shares . Paulson & Co ups share stake in Fedex Corp by 47 percent to 106,800 shares . Paulson & Co takes 74,000 share stake in Alder Biopharmaceuticals Inc . Paulson & Co takes share stake of 628,100 shares in eBay Inc . Paulson & Co cuts share stake in Johnson & Johnson by 72.7 percent to 35,000 shares .Paulson & Co - change in holdings are as of September 30, 2016 and compared with the previous quarter ended as of June 30, 2016.  Full Article

Janssen reports clinical trial collaboration and supply agreement with Amgen to evaluate Daratumumab in combination with Carfilzomib
Thursday, 10 Nov 2016 08:34am EST 

Amgen Inc : Janssen Biotech - financial terms have not been disclosed .Janssen announces clinical trial collaboration and supply agreement with Amgen to evaluate Daratumumab (darzalex®) in combination with Carfilzomib (kyprolis®).  Full Article

Genmab says combination of drugs from J&J, Amgen will be tested in study
Thursday, 10 Nov 2016 08:27am EST 

Genmab : Genmab announces phase III study of daratumumab in combination with carfilzomib in multiple myeloma . Genmab - new phase III study combining daratumumab, carfilzomib,dexamethasone in relapsed/refractory multiple myeloma - dosing expected in 2017 . Genmab - first study under clinical trial collaboration and supply agreement between janssen and amgen .Phase iii study of daratumumab is anticipated to start dosing patients in 2017 and will be sponsored by amgen.  Full Article

British artificial intelligence firm announces license agreement with Janssen
Tuesday, 8 Nov 2016 06:03am EST 

Johnson & Johnson : British artificial intelligence firm announces exclusive license agreement with Janssen for clinical stage drug candidates, facilitated by Johnson & Johnson innovation . Benevolentai - Will have sole right to develop, manufacture and commercialise novel drug candidates in all indications and in all territories . Benevolentai - Intends to begin late stage phase IIB clinical trials in mid 2017 .Benevolentai- financial terms were not disclosed.  Full Article

Johnson & Johnson reports 6.4 pct passive stake in Tracon Pharmaceuticals
Monday, 31 Oct 2016 03:25pm EDT 

:Johnson & Johnson reports 6.4 percent passive stake in Tracon Pharmaceuticals Inc as of Sept 27- SEC Filing.  Full Article

More From Around the Web

Genmab and J&J's cancer drug set for blockbuster sales this year

COPENHAGEN Danish biotech drugmaker Genmab expects sales of Darzalex, used to fight cancer in bone marrow, to surpass $1 billion this year to become a blockbuster drug, the company said on Wednesday.